Transgenic_JJ
expression_NN
of_IN
PML\/RARalpha_NN
impairs_VBZ
myelopoiesis_NN
._.

The_DT
translocation_NN
found_VBN
in_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
rearranges_VBZ
the_DT
promyelocytic_JJ
leukemia_NN
gene_NN
-LRB-_-LRB-
PML_NN
-RRB-_-RRB-
on_IN
chromosome_NN
15_CD
with_IN
the_DT
retinoic_JJ
acid_NN
receptor_NN
alpha_NN
-LRB-_-LRB-
RARalpha_NN
-RRB-_-RRB-
on_IN
chromosome_NN
17_CD
._.

This_DT
yields_VBZ
a_DT
fusion_NN
transcript_NN
,_,
PML\/RARalpha_NN
,_,
a_DT
transcription_NN
factor_NN
with_IN
reported_VBN
dominant_JJ
negative_JJ
functions_NNS
in_IN
the_DT
absence_NN
of_IN
hormone_NN
._.

Clinical_JJ
remissions_NNS
induced_VBN
with_IN
all-trans_JJ
retinoic_JJ
acid_NN
-LRB-_-LRB-
RA_NN
-RRB-_-RRB-
treatment_NN
in_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
are_VBP
linked_VBN
to_TO
PML\/RARalpha_NN
expression_NN
in_IN
leukemic_JJ
cells_NNS
._.

To_TO
evaluate_VB
the_DT
PML\/RARalpha_NN
role_NN
in_IN
myelopoiesis_NN
,_,
transgenic_JJ
mice_NNS
expressing_VBG
PML\/RARalpha_NN
were_VBD
engineered_VBN
._.

A_DT
full-length_JJ
PML\/RARalpha_NN
cDNA_NN
driven_VBN
by_IN
the_DT
CD11b_NN
promoter_NN
was_VBD
expressed_VBN
in_IN
transgenic_JJ
mice_NNS
._.

Expression_NN
was_VBD
confirmed_VBN
in_IN
the_DT
bone_NN
marrow_NN
with_IN
a_DT
reverse_JJ
transcription_NN
PCR_NN
assay_NN
._.

Basal_JJ
total_JJ
white_JJ
blood_NN
cell_NN
and_CC
granulocyte_NN
counts_NNS
did_VBD
not_RB
appreciably_RB
differ_VB
between_IN
PML\/RARalpha_NN
transgenic_JJ
and_CC
control_NN
mice_NNS
._.

Cell_NN
sorter_NN
analysis_NN
of_IN
CD11b_NN
+_CC
bone_NN
marrow_NN
cells_NNS
revealed_VBD
similar_JJ
CD11b_NN
+_JJ
populations_NNS
in_IN
transgenic_JJ
and_CC
control_JJ
mice_NNS
._.

However_RB
,_,
in_FW
vitro_FW
clonal_JJ
growth_NN
assays_NNS
performed_VBN
on_IN
peripheral_JJ
blood_NN
from_IN
transgenic_JJ
versus_CC
control_NN
mice_NNS
revealed_VBD
a_DT
marked_JJ
reduction_NN
of_IN
myeloid_JJ
progenitors_NNS
,_,
especially_RB
in_IN
those_DT
responding_VBG
to_TO
granulocyte\/macrophage_JJ
colony-stimulating_JJ
factor_NN
._.

Granulocyte\/macrophage_NN
colony-stimulating_JJ
factor_NN
and_CC
kit_NN
ligand_NN
cotreatment_NN
did_VBD
not_RB
overcome_VB
this_DT
inhibition_NN
._.

Impaired_JJ
myelopoiesis_NN
in_FW
vivo_FW
was_VBD
shown_VBN
by_IN
stressing_VBG
these_DT
mice_NNS
with_IN
sublethal_JJ
irradiation_NN
._.

Following_VBG
irradiation_NN
,_,
PML\/RARalpha_NN
transgenic_JJ
mice_NNS
,_,
as_IN
compared_VBN
with_IN
controls_NNS
,_,
more_RBR
rapidly_RB
depressed_VBD
peripheral_JJ
white_JJ
blood_NN
cell_NN
and_CC
granulocyte_NN
counts_NNS
._.

As_IN
expected_VBN
,_,
nearly_RB
all_DT
control_JJ
mice_NNS
-LRB-_-LRB-
94.4_CD
%_NN
-RRB-_-RRB-
survived_VBD
irradiation_NN
,_,
yet_CC
this_DT
irradiation_NN
was_VBD
lethal_JJ
to_TO
45.8_CD
%_NN
of_IN
PML\/RARalpha_NN
transgenic_JJ
mice_NNS
._.

Lethality_NN
was_VBD
associated_VBN
with_IN
more_RBR
severe_JJ
leukopenia_NN
in_IN
transgenic_JJ
versus_CC
control_NN
mice_NNS
._.

Retinoic_JJ
acid_NN
treatment_NN
of_IN
irradiated_JJ
PML\/RARalpha_NN
mice_NNS
enhanced_VBD
granulocyte_NN
recovery_NN
._.

These_DT
data_NNS
suggest_VBP
that_IN
abnormal_JJ
myelopoiesis_NN
due_JJ
to_TO
PML\/RARalpha_NN
expression_NN
is_VBZ
an_DT
early_JJ
event_NN
in_IN
oncogenic_JJ
transformation_NN
._.

